Recent progress of epigallocatechin 3-gallate for treatment of Parkinson's disease

Xin-Ling DING; Hui-Yan SUN; Hui-Yan SUN; Qiang LI; Hong-Quan WANG

Return

Recent progress of epigallocatechin 3-gallate for treatment of Parkinson's disease

Author: Xin-Ling DING ¹ ; Hui-Yan SUN ² ; Hui-Yan SUN ³ ; Qiang LI ⁴ ; Hong-Quan WANG ⁵
Author Information

1. School of Basic Medicine
2. The Department of Medical, Chifeng University
3. Key Laboratory of Human Genetic Diseases in Inner Mongolia
4. Dept of Neurology, The Affiliated Hospital of Chifeng University
5. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer
Publication Type:Journal Article
Keywords: apoptosis; EGCG; neuroinflammation; neuroprotection; oxidative stress; Parkinson's disease; α-synuclein
From: Chinese Pharmacological Bulletin 2023;39(10):1806-1810
CountryChina
Language:Chinese
Abstract: Epigallocatechin 3-gallate (EGCG) is an abundant polyphenolie component originating from green tea extract that has exhibited versatile bioactivities in combating several diseases. During the last decade, EGCG are effective in experimental models of Parkinson's disease (PD). Several experimental studies suggest the pleiotropic neuroprotective effects, aiding to EGCG as an appealing therapeutic strategy in PD. Therefore, in this review we focus on the effects of EGCG on anti-apoptosis, anti-oxidant, anti-inflammation, modulation of dopamine production, and the aggregation of a-synuclein. We aim to compile the recent updates and cellular and molecular mechanisms of neuroprotection of EGCG in PD. This review highlights the pharmacological features of EGCG and its therapeutic implications in PD.